patients were treated with an anthracycline-based chemotherapy regimen.
患者接受了基于蒽环类的化疗方案治疗。
doxorubicin is a widely used anthracycline antibiotic.
多柔比星是一种广泛使用的蒽环类抗生素。
clinical guidelines recommend anthracycline therapy for this cancer type.
临床指南推荐对该种癌症类型进行蒽环类药物治疗。
the patient developed anthracycline-induced cardiotoxicity during treatment.
患者在治疗期间出现了蒽环类药物诱发的心脏毒性。
doctors must monitor the cumulative anthracycline dose carefully.
医生必须仔细监测蒽环类药物的累积剂量。
researchers are developing new anthracycline analogues with fewer side effects.
研究人员正在开发副作用较小的新型蒽环类类似物。
resistance to anthracycline drugs remains a major clinical challenge.
对蒽环类药物的耐药性仍然是一个主要的临床挑战。
the study compared the efficacy of taxane and anthracycline combinations.
该研究比较了紫杉烷和蒽环类组合的疗效。
dexrazoxane is used to protect the heart during anthracycline administration.
右雷佐生用于在蒽环类药物给药期间保护心脏。
anthracycline extravasation can cause severe tissue necrosis.
蒽环类药物外渗可导致严重的组织坏死。
biomarkers are needed to predict anthracycline response in patients.
需要生物标志物来预测患者对蒽环类药物的反应。
advancements in liposomal anthracycline delivery have improved safety profiles.
脂质体蒽环类药物递送的进步提高了安全性。
patients were treated with an anthracycline-based chemotherapy regimen.
患者接受了基于蒽环类的化疗方案治疗。
doxorubicin is a widely used anthracycline antibiotic.
多柔比星是一种广泛使用的蒽环类抗生素。
clinical guidelines recommend anthracycline therapy for this cancer type.
临床指南推荐对该种癌症类型进行蒽环类药物治疗。
the patient developed anthracycline-induced cardiotoxicity during treatment.
患者在治疗期间出现了蒽环类药物诱发的心脏毒性。
doctors must monitor the cumulative anthracycline dose carefully.
医生必须仔细监测蒽环类药物的累积剂量。
researchers are developing new anthracycline analogues with fewer side effects.
研究人员正在开发副作用较小的新型蒽环类类似物。
resistance to anthracycline drugs remains a major clinical challenge.
对蒽环类药物的耐药性仍然是一个主要的临床挑战。
the study compared the efficacy of taxane and anthracycline combinations.
该研究比较了紫杉烷和蒽环类组合的疗效。
dexrazoxane is used to protect the heart during anthracycline administration.
右雷佐生用于在蒽环类药物给药期间保护心脏。
anthracycline extravasation can cause severe tissue necrosis.
蒽环类药物外渗可导致严重的组织坏死。
biomarkers are needed to predict anthracycline response in patients.
需要生物标志物来预测患者对蒽环类药物的反应。
advancements in liposomal anthracycline delivery have improved safety profiles.
脂质体蒽环类药物递送的进步提高了安全性。
探索常用高频词汇